Fatty acid oxidation abnormalities in childhood-onset spinal muscular atrophy: primary or secondary defect(s)?
- PMID: 7748356
- DOI: 10.1016/0887-8994(94)00100-g
Fatty acid oxidation abnormalities in childhood-onset spinal muscular atrophy: primary or secondary defect(s)?
Abstract
The purpose of this study was to further identify and quantify the fatty acid oxidation abnormalities in spinal muscular atrophy, correlate these with disease severity, and identify specific underlying defect(s). Fifteen children with spinal muscular atrophy (3 type I, 8 type II, 4 type III) were studied. Serum carnitine total/free ratios demonstrated a tendency toward an increased esterified fraction ranging 35-58% of total carnitine (normal: 25-30% of total) in younger children with types I and II. The remaining type II and III patients, older than 23 months of age at sampling, had normal esterified carnitine levels. Urinary organic acid analysis demonstrated mild to moderate medium-chain dicarboxylic aciduria in type I patients and normal, mild, or moderate increases in short-chain and medium-chain organic acids in type II patients. In the type III group, the organic acids were normal except for one patient with mild medium-chain dicarboxylic aciduria. Muscle intramitochondrial beta-oxidation was measured in 5 children (2 type I, 2 type II, and 1 type III) and a significant reduction in the activities of short-chain L-3-hydroxyacyl-CoA dehydrogenase, long-chain L-3-hydroxyacyl-CoA dehydrogenase, acetoacetyl-CoA thiolase, and 3-ketoacyl-CoA thiolase were found; however, normal crotonase activity was documented. Most strikingly, there was a marked increase (3- to 5-fold) in the activity ratios of crotonase to L-3-hydroxyacyl-CoA dehydrogenase and thiolase activities with both short- and long-chain substrates. The combined abnormalities suggest a defect in a mitochondrial multifunctional enzyme complex, distinct from the trifunctional enzyme. These abnormalities may be either primary or secondary and may respond to dietary measures to reduce the dependence on fatty acid oxidation.
Similar articles
-
Combined enzyme defect of mitochondrial fatty acid oxidation.J Clin Invest. 1992 Oct;90(4):1219-25. doi: 10.1172/JCI115983. J Clin Invest. 1992. PMID: 1401059 Free PMC article.
-
Differentiation of long-chain fatty acid oxidation disorders using alternative precursors and acylcarnitine profiling in fibroblasts.Mol Genet Metab. 2006 Jan;87(1):40-7. doi: 10.1016/j.ymgme.2005.09.018. Epub 2005 Nov 16. Mol Genet Metab. 2006. PMID: 16297647
-
3-Hydroxydicarboxylic and 3-ketodicarboxylic aciduria in three patients: evidence for a new defect in fatty acid oxidation at the level of 3-ketoacyl-CoA thiolase.Clin Chem. 1993 May;39(5):897-901. Clin Chem. 1993. PMID: 8485884
-
Clinical and biochemical features of fatty acid oxidation disorders.Curr Opin Pediatr. 1998 Dec;10(6):615-21. doi: 10.1097/00008480-199810060-00014. Curr Opin Pediatr. 1998. PMID: 9848022 Review.
-
Mitochondrial β-oxidation of saturated fatty acids in humans.Mitochondrion. 2019 May;46:73-90. doi: 10.1016/j.mito.2018.02.009. Epub 2018 Mar 15. Mitochondrion. 2019. PMID: 29551309 Review.
Cited by
-
Genomic Variability in the Survival Motor Neuron Genes (SMN1 and SMN2): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development.Int J Mol Sci. 2021 Jul 23;22(15):7896. doi: 10.3390/ijms22157896. Int J Mol Sci. 2021. PMID: 34360669 Free PMC article. Review.
-
Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental Therapies.Paediatr Drugs. 2022 Nov;24(6):585-602. doi: 10.1007/s40272-022-00529-8. Epub 2022 Aug 27. Paediatr Drugs. 2022. PMID: 36028610 Review.
-
Glucose metabolism and pancreatic defects in spinal muscular atrophy.Ann Neurol. 2012 Aug;72(2):256-68. doi: 10.1002/ana.23582. Ann Neurol. 2012. PMID: 22926856 Free PMC article.
-
Abnormal fatty acid metabolism is a core component of spinal muscular atrophy.Ann Clin Transl Neurol. 2019 Aug;6(8):1519-1532. doi: 10.1002/acn3.50855. Epub 2019 Jul 26. Ann Clin Transl Neurol. 2019. PMID: 31402618 Free PMC article.
-
Efficacy and Safety of Valproic Acid for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis.CNS Drugs. 2019 Mar;33(3):239-250. doi: 10.1007/s40263-019-00606-6. CNS Drugs. 2019. PMID: 30796634
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical